Insmed (INSM) Net Cash Flow Growth (1y) (2011 - 2026)
Insmed (INSM) Net Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,583.17 Bn | 67,582.89 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,947.22 Bn | 1,947.15 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 473.21 Bn | 468.42 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 123.29 Bn | 116.04 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.29 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 63.09 Bn | 63.09 Bn | - | - |
| 8 | Argenx Se | 56.63 Bn | 51.45 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.79 Bn | 37.79 Bn | - | - |
| 10 | Insmed | 22.91 Bn | 21.69 Bn | 258.54 Mn | 147.35% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 147.35% |
| Dec 31, 2025 | 84.76% |
| Sep 30, 2025 | -20.50% |
| Jun 30, 2025 | 35.03% |
| Mar 31, 2025 | -233.57% |
| Dec 31, 2024 | 1,752.77% |
| Sep 30, 2024 | -515.29% |
| Jun 30, 2024 | 284.83% |
| Mar 31, 2024 | 208.76% |
| Dec 31, 2023 | -100.87% |
| Sep 30, 2023 | -3,783.94% |
| Jun 30, 2023 | -256.57% |
| Mar 31, 2023 | 47.48% |
| Dec 31, 2022 | 609.52% |
| Sep 30, 2022 | 95.95% |
| Jun 30, 2022 | -119.07% |
| Mar 31, 2022 | -63.01% |
| Dec 31, 2021 | -130.28% |
| Sep 30, 2021 | -52.51% |
| Jun 30, 2021 | 143.60% |